| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V70196 | (E)-Akt inhibitor-IV ((E)-AKTIV) | 959841-49-7 | (E)-Akt inhibitor-IV ((E)-AKTIV) is a PI3K-Akt inhibitor (antagonist) with significant cell toxicity/cytotoxicity. |
|
V70211 | 22-(4′-py)-JA (22-(4′-Pyridinecarbonyl) jorunnamycin A) | 1178895-15-2 | 22-(4′-py)-JA is a semi-synthetic analogue of kunamycin A (JA), which can be extracted from Xestospongia sp. |
|
V51368 | 24-Methylene cycloartanyl ferulate | 469-36-3 | Akt1 inhibitor |
|
V69649 | Ack1 inhibitor 1 | 2924415-92-7 | Ack1 inhibitor 1 is a specific, orally bioactive ACK1 kinase inhibitor (antagonist) with IC50 of 2.1 nM. |
|
V70201 | Adropin (34-76) (human, mouse, rat) | 1802086-30-1 | Adropin (34-76) (human, mouse, rat) modulates fuel selection preference in skeletal muscle. |
|
V77875 | AKT-IN-11 | AKT-IN-11 is one of the most effective anti-bacterial agents against human liver cancer Bel-7402 cell line, with IC501.15μM. | |
|
V128448 | AKT-IN-27 | AKT-IN-27 is a potential anticancer drug whose mechanism of action is through selectively targeting the Akt-driven signaling pathway. | |
|
V70221 | AKT-IN-5 | 1402608-05-2 | AKT-IN-5 (Example 8) is an Akt inhibitor (antagonist) with IC50s of 450 nM and 400 nM for Akt1 and Akt2, respectively. |
|
V89044 | Akt1-IN-4 | 3033577-05-5 | Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with IC50 value less than 15 nM. |
|
V0173 | Akti-1/2 (AKT inhibitor VIII) | 612847-09-3 | Akti-1/2 (known also as AKT inhibitor VIII), aquinoxaline-based compound,is a novel, potent, selective,cell-permeable and allosteric inhibitor of Akt1/2 with potential anticancer activity. |
|
V70212 | APN/AKT-IN-1 | 2854340-31-9 | APN/AKT-IN-1 is a potent dual (bifunctional) inhibitor of APN and AKT with IC50s of 0.21 and 0.27 μM, respectively. |
|
V116788 | Archexin | 944440-48-6 | Archexin is an antisense oligonucleotide (ASO) that targets Akt1 and is currently being used in research on metastatic renal cell carcinoma. |
|
V0170 | AT13148 | 1056901-62-2 | AT13148 is a novel, potent, orally bioavailable, ATP-competitive, multi-AGC kinase inhibitor with potential anticancer activity. |
|
V0161 | AT7867 | 857531-00-1 | AT7867 isa novel, highly potent, orally bioavailable and ATP-competitive inhibitorofAkt1/Akt2/Akt3andp70S6K/PKA (protein kinase A) with potential anticancer activity. |
|
V129709 | AZ14289671 | 3101563-22-5 | AZ14289671 is an orally effective, blood-brain barrier-crossing tyrosine kinase inhibitor (TKI) that specifically targets non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations (EGFRExon20Ins) while having less effect on wild-type EGFR, thereby reducing off-target toxicities such as rash and diarrhea. |
|
V0163 | CCT128930 | 885499-61-6 | CCT128930 is a novel, potent, ATP-competitive and selective pyrrolopyrimidine-basedinhibitor of Akt2 (IC50 = 6 nM in a cell-free assay)with potential anticancer activity. |
|
V0172 | Dordaviprone (TIC10; imipridone, ONC201) | 1616632-77-9 | Dordaviprone (TIC10; imipridone, ONC201), an imipridone compound,isa novel, potent, orally bioavailable, brain/BBB penetrant, and stable tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)inducer with potential anticancer activity. |
|
V4633 | GSK2110183 analog HCl | 2070009-64-0 | GSK2110183 analog HCl, an analog ofAfuresertib, is a potent, orally bioavailable andATP-competitive Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. |
|
V0157 | GSK-690693 | 937174-76-0 | GSK690693, an aminofurazan derivative, is a novel, potent andATP-competitivepan-Akt inhibitor targeting Akt1/2/3 with potential anticancer activity. |
|
V69802 | Insulin Detemir | 169148-63-4 | Insulin Detemir is an artificial insulin that controls blood sugar levels. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
